Autologous adipose-derived mesenchymal stem cell therapy - Cellular Biomedicine Group

Drug Profile

Autologous adipose-derived mesenchymal stem cell therapy - Cellular Biomedicine Group

Alternative Names: Adipose-derived mesenchymal progenitor cell therapy - Cellular Biomedicine Group; haMPC; MPC; ReJoin®

Latest Information Update: 21 Feb 2017

Price : $50

At a glance

  • Originator Cellular Biomedicine Group; Shanghai Jiao Tong University
  • Class Antineoplastics; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Osteoarthritis
  • Clinical Phase Unknown Cartilage disorders
  • Preclinical Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 01 Nov 2016 Cellular Biomedicine completes a phase IIb trial for Osteoarthritis in China (NCT02162693)
  • 12 Aug 2016 Autologous adipose-derived mesenchymal stem cell therapy is still in phase II trials for Osteoarthritis in China (Intra-articular)
  • 13 Jan 2016 Efficacy and adverse events data from a phase IIb trial in Osteoarthritis released by Cellular Biomedicine Group
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top